| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 13 | 2025 | 1392 | 3.120 |
Why?
|
| Transcription Factors | 25 | 2025 | 1540 | 3.010 |
Why?
|
| Acupuncture Therapy | 7 | 2022 | 20 | 2.910 |
Why?
|
| Cancer Survivors | 8 | 2023 | 120 | 2.780 |
Why?
|
| Adaptor Proteins, Signal Transducing | 17 | 2025 | 431 | 2.610 |
Why?
|
| Integrative Medicine | 5 | 2022 | 32 | 2.510 |
Why?
|
| Hedgehog Proteins | 15 | 2017 | 116 | 2.280 |
Why?
|
| Breast Neoplasms | 13 | 2023 | 1211 | 2.100 |
Why?
|
| Integrative Oncology | 3 | 2022 | 3 | 2.030 |
Why?
|
| Medical Oncology | 6 | 2019 | 68 | 1.930 |
Why?
|
| Nuclear Proteins | 10 | 2025 | 785 | 1.660 |
Why?
|
| DNA-Binding Proteins | 12 | 2025 | 1196 | 1.580 |
Why?
|
| Carcinogenesis | 5 | 2025 | 131 | 1.520 |
Why?
|
| Aromatase Inhibitors | 3 | 2019 | 25 | 1.500 |
Why?
|
| Trans-Activators | 12 | 2022 | 312 | 1.300 |
Why?
|
| Acupuncture | 2 | 2020 | 4 | 1.260 |
Why?
|
| Signal Transduction | 36 | 2025 | 3070 | 1.250 |
Why?
|
| Mesoderm | 6 | 2017 | 85 | 1.110 |
Why?
|
| Phosphoproteins | 12 | 2025 | 221 | 1.100 |
Why?
|
| Cell Cycle Proteins | 8 | 2025 | 396 | 1.090 |
Why?
|
| Complementary Therapies | 4 | 2021 | 63 | 1.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 115 | 0.990 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2025 | 9 | 0.920 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2014 | 48 | 0.910 |
Why?
|
| Bereavement | 1 | 2025 | 18 | 0.900 |
Why?
|
| Sarcoma | 1 | 2025 | 36 | 0.900 |
Why?
|
| Music Therapy | 1 | 2025 | 20 | 0.890 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 58 | 0.880 |
Why?
|
| Survivors | 3 | 2023 | 182 | 0.870 |
Why?
|
| Narration | 1 | 2025 | 51 | 0.860 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 349 | 0.860 |
Why?
|
| Mice | 41 | 2025 | 11003 | 0.860 |
Why?
|
| Music | 1 | 2025 | 80 | 0.840 |
Why?
|
| Gastrointestinal Tract | 3 | 2017 | 187 | 0.820 |
Why?
|
| Adaptation, Psychological | 1 | 2025 | 270 | 0.780 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2022 | 1 | 0.760 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 276 | 0.730 |
Why?
|
| Humans | 54 | 2025 | 64238 | 0.720 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 63 | 0.700 |
Why?
|
| Animals | 52 | 2025 | 20961 | 0.700 |
Why?
|
| Parents | 1 | 2025 | 395 | 0.670 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 145 | 0.670 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 48 | 0.660 |
Why?
|
| Cell Differentiation | 9 | 2025 | 1365 | 0.660 |
Why?
|
| Quality of Life | 5 | 2023 | 1257 | 0.660 |
Why?
|
| Intestines | 3 | 2020 | 169 | 0.630 |
Why?
|
| Uveal Neoplasms | 1 | 2019 | 50 | 0.630 |
Why?
|
| Transcription, Genetic | 7 | 2024 | 883 | 0.630 |
Why?
|
| Arthralgia | 1 | 2019 | 58 | 0.590 |
Why?
|
| Wnt Proteins | 11 | 2013 | 100 | 0.580 |
Why?
|
| Mice, Transgenic | 14 | 2025 | 1297 | 0.570 |
Why?
|
| Fatigue | 2 | 2019 | 114 | 0.570 |
Why?
|
| Nerve Tissue Proteins | 6 | 2016 | 429 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 727 | 0.570 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2013 | 129 | 0.570 |
Why?
|
| Stem Cells | 5 | 2020 | 262 | 0.560 |
Why?
|
| Zinc Finger Protein Gli2 | 4 | 2024 | 26 | 0.550 |
Why?
|
| Low Back Pain | 1 | 2019 | 115 | 0.540 |
Why?
|
| Epithelium | 1 | 2017 | 96 | 0.530 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 125 | 0.530 |
Why?
|
| Zinc Finger Protein GLI1 | 6 | 2022 | 31 | 0.520 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 50 | 0.510 |
Why?
|
| Chronic Pain | 1 | 2019 | 156 | 0.500 |
Why?
|
| Melanoma | 1 | 2019 | 331 | 0.490 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 306 | 0.480 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 41 | 0.480 |
Why?
|
| Rhabdomyosarcoma | 2 | 2013 | 16 | 0.480 |
Why?
|
| beta Catenin | 4 | 2013 | 99 | 0.470 |
Why?
|
| Hot Flashes | 3 | 2020 | 101 | 0.470 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2022 | 36 | 0.460 |
Why?
|
| Muscle Proteins | 1 | 2016 | 117 | 0.450 |
Why?
|
| Female | 26 | 2025 | 33350 | 0.450 |
Why?
|
| Cell Proliferation | 8 | 2020 | 1001 | 0.450 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 343 | 0.450 |
Why?
|
| Cell Lineage | 3 | 2013 | 273 | 0.450 |
Why?
|
| Zebrafish Proteins | 8 | 2004 | 159 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 534 | 0.440 |
Why?
|
| Medicare | 1 | 2019 | 611 | 0.440 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 356 | 0.430 |
Why?
|
| Repressor Proteins | 5 | 2021 | 348 | 0.430 |
Why?
|
| Proteins | 9 | 2005 | 760 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2012 | 329 | 0.420 |
Why?
|
| GTP-Binding Proteins | 3 | 1998 | 87 | 0.420 |
Why?
|
| Cell Movement | 1 | 2016 | 466 | 0.410 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2013 | 14 | 0.400 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2013 | 10 | 0.400 |
Why?
|
| Body Patterning | 2 | 2014 | 82 | 0.400 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 1494 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2023 | 207 | 0.380 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 347 | 0.370 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 666 | 0.370 |
Why?
|
| Genes, ras | 1 | 2012 | 27 | 0.370 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2002 | 128 | 0.370 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2025 | 204 | 0.360 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2021 | 7 | 0.350 |
Why?
|
| Adult | 11 | 2025 | 17116 | 0.350 |
Why?
|
| Biomedical Research | 3 | 2019 | 270 | 0.340 |
Why?
|
| Drosophila melanogaster | 4 | 2021 | 500 | 0.330 |
Why?
|
| Zinc Finger Protein Gli3 | 3 | 2016 | 9 | 0.330 |
Why?
|
| Mammals | 2 | 2010 | 219 | 0.330 |
Why?
|
| Receptors, LDL | 4 | 2004 | 35 | 0.320 |
Why?
|
| Smoothened Receptor | 6 | 2013 | 27 | 0.310 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 243 | 0.310 |
Why?
|
| Receptors, Cell Surface | 4 | 2014 | 430 | 0.310 |
Why?
|
| Gene Expression Regulation | 4 | 2005 | 1621 | 0.300 |
Why?
|
| Fibroblast Growth Factor 8 | 1 | 2009 | 4 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2009 | 19 | 0.300 |
Why?
|
| Middle Aged | 11 | 2025 | 17898 | 0.300 |
Why?
|
| Embryo, Mammalian | 2 | 2010 | 156 | 0.300 |
Why?
|
| Extremities | 1 | 2009 | 46 | 0.290 |
Why?
|
| Vertebrates | 1 | 2009 | 44 | 0.290 |
Why?
|
| Weight Gain | 1 | 2010 | 168 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 497 | 0.290 |
Why?
|
| Cell Transdifferentiation | 2 | 2025 | 15 | 0.290 |
Why?
|
| Pain Management | 2 | 2022 | 169 | 0.290 |
Why?
|
| Protein Binding | 6 | 2022 | 1618 | 0.280 |
Why?
|
| 3T3 Cells | 10 | 2002 | 112 | 0.280 |
Why?
|
| Neoplasms, Experimental | 2 | 2009 | 78 | 0.260 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2021 | 644 | 0.260 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2176 | 0.260 |
Why?
|
| United States | 5 | 2022 | 7923 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 181 | 0.260 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 2013 | 34 | 0.260 |
Why?
|
| Culturally Competent Care | 2 | 2023 | 17 | 0.240 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 2238 | 0.240 |
Why?
|
| Neurons | 3 | 2025 | 934 | 0.240 |
Why?
|
| Mullerian Ducts | 1 | 2025 | 5 | 0.230 |
Why?
|
| Myofibroblasts | 1 | 2025 | 16 | 0.230 |
Why?
|
| Drosophila Proteins | 3 | 2018 | 704 | 0.230 |
Why?
|
| Age Factors | 3 | 2019 | 1569 | 0.230 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2025 | 2 | 0.230 |
Why?
|
| Zona Glomerulosa | 1 | 2025 | 1 | 0.230 |
Why?
|
| Adrenal Cortex | 1 | 2025 | 3 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2616 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 199 | 0.230 |
Why?
|
| Grief | 1 | 2025 | 19 | 0.230 |
Why?
|
| Immunoblotting | 2 | 2017 | 206 | 0.230 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2737 | 0.220 |
Why?
|
| Child | 3 | 2025 | 4583 | 0.220 |
Why?
|
| Disease Progression | 2 | 2019 | 1176 | 0.220 |
Why?
|
| Vesicular Transport Proteins | 1 | 2025 | 115 | 0.210 |
Why?
|
| Postmenopause | 2 | 2019 | 238 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5691 | 0.210 |
Why?
|
| Young Adult | 4 | 2025 | 4776 | 0.210 |
Why?
|
| Molecular Sequence Data | 7 | 2016 | 1997 | 0.210 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2002 | 62 | 0.210 |
Why?
|
| Integrin alpha6beta1 | 2 | 2015 | 34 | 0.210 |
Why?
|
| Aged | 5 | 2025 | 14648 | 0.210 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 147 | 0.200 |
Why?
|
| Integrases | 3 | 2009 | 38 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2025 | 575 | 0.190 |
Why?
|
| Mentoring | 1 | 2023 | 52 | 0.190 |
Why?
|
| Hope | 1 | 2022 | 10 | 0.190 |
Why?
|
| Antisocial Personality Disorder | 1 | 2022 | 37 | 0.190 |
Why?
|
| Interleukin-33 | 1 | 2022 | 18 | 0.190 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 34 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 5520 | 0.190 |
Why?
|
| Risk Factors | 3 | 2019 | 5339 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 544 | 0.180 |
Why?
|
| Pain | 2 | 2022 | 407 | 0.180 |
Why?
|
| Logistic Models | 2 | 2019 | 1270 | 0.180 |
Why?
|
| Microglia | 1 | 2025 | 250 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 174 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2022 | 85 | 0.180 |
Why?
|
| Gene Deletion | 2 | 2021 | 312 | 0.180 |
Why?
|
| Mitochondria | 1 | 2025 | 384 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 125 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 217 | 0.180 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 18 | 0.170 |
Why?
|
| Genomic Instability | 1 | 2021 | 55 | 0.170 |
Why?
|
| Alleles | 4 | 2020 | 448 | 0.170 |
Why?
|
| Cell Nucleus | 2 | 2018 | 632 | 0.170 |
Why?
|
| Inflammation | 2 | 2025 | 1162 | 0.170 |
Why?
|
| COS Cells | 5 | 2002 | 174 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 82 | 0.170 |
Why?
|
| Social Support | 1 | 2023 | 376 | 0.170 |
Why?
|
| DNA Transposable Elements | 1 | 2021 | 139 | 0.170 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 3 | 0.160 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2020 | 8 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 34 | 0.160 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 87 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 108 | 0.160 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2019 | 1 | 0.160 |
Why?
|
| Male | 11 | 2025 | 30294 | 0.160 |
Why?
|
| Phosphorylation | 6 | 2019 | 948 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2021 | 193 | 0.150 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2019 | 6 | 0.150 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2019 | 13 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2019 | 130 | 0.150 |
Why?
|
| SOXC Transcription Factors | 2 | 2022 | 9 | 0.150 |
Why?
|
| Erdheim-Chester Disease | 1 | 2019 | 2 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 166 | 0.150 |
Why?
|
| Survivorship | 1 | 2019 | 14 | 0.150 |
Why?
|
| Melanocytes | 1 | 2019 | 76 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2019 | 49 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 209 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 410 | 0.150 |
Why?
|
| Mice, 129 Strain | 2 | 2020 | 41 | 0.150 |
Why?
|
| Internet | 2 | 2019 | 467 | 0.150 |
Why?
|
| Reproductive Health | 1 | 2018 | 25 | 0.140 |
Why?
|
| Kidney | 1 | 2021 | 455 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 344 | 0.140 |
Why?
|
| Yeasts | 1 | 2018 | 49 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2018 | 28 | 0.140 |
Why?
|
| Mice, Knockout | 4 | 2025 | 2140 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 201 | 0.140 |
Why?
|
| Web Browser | 1 | 2017 | 7 | 0.140 |
Why?
|
| Comprehensive Health Care | 1 | 2017 | 19 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 151 | 0.140 |
Why?
|
| Medulloblastoma | 2 | 2008 | 12 | 0.140 |
Why?
|
| Acyltransferases | 1 | 2017 | 33 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2019 | 627 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 437 | 0.130 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2016 | 2 | 0.130 |
Why?
|
| Menopause, Premature | 1 | 2017 | 26 | 0.130 |
Why?
|
| Heterografts | 1 | 2017 | 66 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 374 | 0.130 |
Why?
|
| Social Media | 1 | 2019 | 127 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 34 | 0.130 |
Why?
|
| Transfection | 6 | 2016 | 695 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 529 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 20 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2013 | 153 | 0.130 |
Why?
|
| Cell Membrane | 2 | 2018 | 501 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 33 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2016 | 143 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2020 | 3315 | 0.120 |
Why?
|
| Women's Health | 1 | 2019 | 374 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 460 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 259 | 0.120 |
Why?
|
| RNA Interference | 3 | 2016 | 618 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 91 | 0.120 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 13 | 0.120 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2015 | 2 | 0.120 |
Why?
|
| Carcinoma, Lobular | 1 | 2016 | 26 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 237 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 36 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 44 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2013 | 1597 | 0.120 |
Why?
|
| Adolescent | 2 | 2025 | 6304 | 0.120 |
Why?
|
| Mutation | 4 | 2019 | 2629 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 462 | 0.110 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 102 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 263 | 0.110 |
Why?
|
| Medicaid | 1 | 2019 | 362 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 278 | 0.110 |
Why?
|
| Receptors, Notch | 2 | 2016 | 106 | 0.110 |
Why?
|
| Macrophages | 1 | 2020 | 1053 | 0.110 |
Why?
|
| Serum Response Factor | 3 | 1998 | 5 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 726 | 0.110 |
Why?
|
| Time Factors | 4 | 2017 | 3724 | 0.110 |
Why?
|
| Laminin | 1 | 2015 | 78 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 901 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 126 | 0.110 |
Why?
|
| Menopause | 1 | 2017 | 260 | 0.110 |
Why?
|
| Health Promotion | 1 | 2018 | 505 | 0.110 |
Why?
|
| Prevalence | 1 | 2018 | 1407 | 0.110 |
Why?
|
| Regeneration | 1 | 2014 | 101 | 0.100 |
Why?
|
| PAX7 Transcription Factor | 1 | 2013 | 9 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 139 | 0.100 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2013 | 15 | 0.100 |
Why?
|
| Rhabdomyoma | 1 | 2013 | 2 | 0.100 |
Why?
|
| Genome, Human | 1 | 2016 | 240 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2014 | 153 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 9 | 0.100 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 29 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2019 | 759 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 109 | 0.100 |
Why?
|
| Base Sequence | 1 | 2016 | 1332 | 0.100 |
Why?
|
| Aging | 1 | 2019 | 754 | 0.100 |
Why?
|
| Exocrine Glands | 1 | 2013 | 1 | 0.100 |
Why?
|
| Edar Receptor | 1 | 2013 | 1 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 128 | 0.100 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 176 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 460 | 0.100 |
Why?
|
| Autocrine Communication | 1 | 2013 | 30 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 234 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2016 | 1551 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 61 | 0.100 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 40 | 0.090 |
Why?
|
| Hair | 1 | 2013 | 83 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 39 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 297 | 0.090 |
Why?
|
| Models, Animal | 1 | 2013 | 240 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2013 | 614 | 0.090 |
Why?
|
| Biological Evolution | 1 | 2013 | 122 | 0.090 |
Why?
|
| Luciferases | 3 | 2002 | 108 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 260 | 0.090 |
Why?
|
| Protein Transport | 2 | 2003 | 405 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2016 | 42 | 0.090 |
Why?
|
| Smad Proteins | 1 | 2011 | 23 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1187 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2002 | 27 | 0.080 |
Why?
|
| Gastrula | 1 | 2010 | 12 | 0.080 |
Why?
|
| Paracrine Communication | 1 | 2010 | 15 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 747 | 0.080 |
Why?
|
| Philadelphia | 1 | 2010 | 24 | 0.080 |
Why?
|
| Axin Protein | 4 | 2007 | 10 | 0.080 |
Why?
|
| Genes, Reporter | 4 | 2007 | 260 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2012 | 471 | 0.080 |
Why?
|
| Organogenesis | 1 | 2010 | 39 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 54 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 512 | 0.080 |
Why?
|
| Histones | 2 | 2024 | 486 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 783 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 134 | 0.080 |
Why?
|
| Polydactyly | 1 | 2009 | 2 | 0.080 |
Why?
|
| Ectoderm | 1 | 2009 | 11 | 0.080 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 16 | 0.080 |
Why?
|
| Chick Embryo | 1 | 2009 | 46 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 412 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 183 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2009 | 125 | 0.070 |
Why?
|
| Outpatients | 1 | 2010 | 140 | 0.070 |
Why?
|
| Genotype | 3 | 2020 | 668 | 0.070 |
Why?
|
| Thrombin | 2 | 1998 | 22 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2009 | 109 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 495 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 490 | 0.070 |
Why?
|
| GTPase-Activating Proteins | 2 | 1998 | 68 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2024 | 685 | 0.070 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 3 | 2004 | 4 | 0.070 |
Why?
|
| LDL-Receptor Related Proteins | 3 | 2004 | 5 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 285 | 0.070 |
Why?
|
| Sequence Alignment | 3 | 2013 | 302 | 0.070 |
Why?
|
| Patched Receptors | 3 | 2014 | 10 | 0.070 |
Why?
|
| Phenotype | 3 | 2020 | 1222 | 0.070 |
Why?
|
| Cell Line | 3 | 2011 | 2055 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 52 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2021 | 348 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 3450 | 0.070 |
Why?
|
| Stomach | 1 | 2007 | 87 | 0.070 |
Why?
|
| Morphogenesis | 1 | 2007 | 114 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2003 | 709 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 1019 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2001 | 46 | 0.060 |
Why?
|
| Spleen | 1 | 2007 | 482 | 0.060 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 157 | 0.060 |
Why?
|
| Xenopus Proteins | 2 | 2003 | 37 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 272 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2021 | 40 | 0.060 |
Why?
|
| Chimera | 1 | 2005 | 42 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 674 | 0.060 |
Why?
|
| Granulosa Cells | 1 | 2025 | 16 | 0.060 |
Why?
|
| Doxycycline | 1 | 2005 | 47 | 0.060 |
Why?
|
| Ovary | 1 | 2025 | 101 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 103 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2011 | 365 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2025 | 87 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2007 | 401 | 0.050 |
Why?
|
| Dishevelled Proteins | 5 | 2003 | 6 | 0.050 |
Why?
|
| Gene Expression | 2 | 2013 | 851 | 0.050 |
Why?
|
| Patched-1 Receptor | 2 | 2014 | 13 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2025 | 909 | 0.050 |
Why?
|
| Binding Sites | 3 | 2016 | 914 | 0.050 |
Why?
|
| Face | 1 | 2004 | 36 | 0.050 |
Why?
|
| Neural Crest | 1 | 2004 | 28 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 210 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 668 | 0.050 |
Why?
|
| Cell Death | 1 | 2025 | 286 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1561 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 100 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2005 | 266 | 0.050 |
Why?
|
| Ovum | 1 | 2003 | 63 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 526 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 113 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2046 | 0.050 |
Why?
|
| Lipoylation | 1 | 2022 | 5 | 0.050 |
Why?
|
| Crystallization | 1 | 2022 | 101 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 77 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2002 | 4 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 26 | 0.050 |
Why?
|
| Cicatrix | 1 | 2022 | 61 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 162 | 0.040 |
Why?
|
| Point Mutation | 1 | 2002 | 165 | 0.040 |
Why?
|
| Bone Density | 1 | 2002 | 137 | 0.040 |
Why?
|
| Cysteine | 1 | 2001 | 108 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2020 | 9 | 0.040 |
Why?
|
| Cadherins | 1 | 2021 | 82 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 185 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2001 | 133 | 0.040 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2020 | 11 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2020 | 41 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 404 | 0.040 |
Why?
|
| Heart | 1 | 2022 | 288 | 0.040 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 4 | 2000 | 10 | 0.040 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 233 | 0.040 |
Why?
|
| Sexual Health | 1 | 2018 | 8 | 0.040 |
Why?
|
| Endothelins | 1 | 1998 | 3 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 7 | 0.040 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1998 | 9 | 0.040 |
Why?
|
| Myocardium | 1 | 2020 | 288 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 1998 | 26 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Epidermis | 1 | 2018 | 37 | 0.040 |
Why?
|
| Fertility | 1 | 2018 | 83 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1998 | 142 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 735 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 31 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 68 | 0.030 |
Why?
|
| Affect | 1 | 2019 | 127 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1998 | 302 | 0.030 |
Why?
|
| Contraception | 1 | 2018 | 71 | 0.030 |
Why?
|
| Memory | 1 | 2019 | 123 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 283 | 0.030 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2017 | 1 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 161 | 0.030 |
Why?
|
| Mind-Body Therapies | 1 | 2017 | 10 | 0.030 |
Why?
|
| Text Messaging | 1 | 2018 | 86 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 127 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 61 | 0.030 |
Why?
|
| Arsenicals | 1 | 2016 | 7 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2016 | 34 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2016 | 18 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 3 | 2007 | 205 | 0.030 |
Why?
|
| Oxides | 1 | 2016 | 36 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 744 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 766 | 0.030 |
Why?
|
| Chromatin | 1 | 2021 | 616 | 0.030 |
Why?
|
| Digestion | 1 | 2018 | 155 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1272 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2017 | 124 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2016 | 6 | 0.030 |
Why?
|
| Receptor, Notch3 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Leuprolide | 1 | 2016 | 16 | 0.030 |
Why?
|
| Protein Structure, Secondary | 2 | 2011 | 260 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 67 | 0.030 |
Why?
|
| Androstadienes | 1 | 2016 | 41 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 167 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1118 | 0.030 |
Why?
|
| Triazoles | 1 | 2016 | 62 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 79 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 583 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 927 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 130 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 210 | 0.030 |
Why?
|
| Cilia | 1 | 2016 | 156 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 317 | 0.030 |
Why?
|
| Enzyme Activation | 3 | 2001 | 386 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 478 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 389 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 582 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 517 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 869 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1769 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 788 | 0.030 |
Why?
|
| Estradiol | 1 | 2016 | 258 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2016 | 189 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 324 | 0.030 |
Why?
|
| Health Behavior | 1 | 2017 | 474 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 915 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 417 | 0.030 |
Why?
|
| Diet | 1 | 2017 | 533 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 59 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2478 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 872 | 0.020 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 3 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Cell Division | 1 | 2014 | 454 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 197 | 0.020 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 43 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 167 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 134 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 590 | 0.020 |
Why?
|
| Amino Acid Substitution | 2 | 2004 | 239 | 0.020 |
Why?
|
| Xenopus | 2 | 2003 | 55 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2011 | 14 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2011 | 90 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 62 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2604 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 324 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 302 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 174 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 954 | 0.020 |
Why?
|
| Glycogen Synthase Kinases | 2 | 1999 | 3 | 0.020 |
Why?
|
| Wnt1 Protein | 2 | 1999 | 12 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2009 | 30 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1375 | 0.020 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 704 | 0.020 |
Why?
|
| Cerebrum | 1 | 2008 | 16 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1664 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2008 | 110 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 41 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 2018 | 0.020 |
Why?
|
| WT1 Proteins | 1 | 2007 | 5 | 0.020 |
Why?
|
| Transcription Factor 4 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2007 | 5 | 0.020 |
Why?
|
| Cyclin D | 1 | 2007 | 4 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 5 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 6 | 0.020 |
Why?
|
| Endoderm | 1 | 2007 | 47 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2007 | 35 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 215 | 0.020 |
Why?
|
| Cyclins | 1 | 2007 | 42 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2007 | 84 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 192 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 110 | 0.020 |
Why?
|
| Skull | 1 | 2004 | 50 | 0.010 |
Why?
|
| Mandible | 1 | 2002 | 9 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2002 | 10 | 0.010 |
Why?
|
| Palate | 1 | 2002 | 8 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 57 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 180 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 195 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 153 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 185 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2002 | 149 | 0.010 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2000 | 113 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 552 | 0.010 |
Why?
|
| Static Electricity | 1 | 2000 | 168 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 340 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 374 | 0.010 |
Why?
|
| Protein Folding | 1 | 2000 | 268 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1130 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1999 | 375 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2000 | 1159 | 0.010 |
Why?
|
| Biomarkers | 1 | 2002 | 1431 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1999 | 784 | 0.010 |
Why?
|